New Marker for AD on the Horizon?
The chemokine receptor CCR1 might be an early and specific marker of Alzheimer's disease, researchers suggest in the November issue of Annals of Neurology, now available online...
586 RESULTS
Sort By:
The chemokine receptor CCR1 might be an early and specific marker of Alzheimer's disease, researchers suggest in the November issue of Annals of Neurology, now available online...
Three groups presented results of their ongoing effort to incorporate scientific advances of the past quarter-century into a revision of the current diagnostic AD criteria...
The stuff touted to confer anti-aging properties on foods from blueberries to dark chocolate does no good for people with Alzheimer’s disease—and might even make them worse...
As to precisely where the hippocampus starts and stops on a magnetic resonance image, researchers have little consensus...
Is it time for a new diagnostic paradigm for Alzheimer disease?...
It’s a scenario familiar to many clinicians: A patient diagnosed with mild cognitive impairment asks if he or she will eventually develop Alzheimer’s disease.
Like a blue moon, could oligomeric amyloid-β in the cerebrospinal fluid (CSF) be too rare to be informative?...
Identifying people on the verge of dementia before they actually succumb has become somewhat of a Holy Grail for Alzheimer disease research...
Studies support the idea that mitochondrial changes drive aging and AD pathogenesis.
The first report on PBB3, the latest tau ligand for brain imaging under development, suggests it binds all types of tau aggregate.
People with neurodegeneration but not brain amyloid surface in two new studies of preclinical AD, suggesting this odd population is both legitimate and potentially large.
Allegations of falsified data embroil Japanese ADNI; project leaders respond that data corrections followed quality-control procedures.
Imaging technique borrowed from cancer care shows that leaks are worse in people who are cognitively impaired.
In separate studies, researchers propose that high CSF ferritin and D-serine could become biomarkers to predict declining cognition in Alzheimer’s disease.
Levels of a neuronal protein in blood correlated with rate of decline in two U.K. cohorts.